<DOC>
	<DOCNO>NCT01422408</DOCNO>
	<brief_summary>This phase II trial study well give fluocinonide cream work treat symptom vaginal dryness painful sexual intercourse patient breast cancer undergo hormone therapy . Fluocinonide cream may prevent lessen vaginal dryness painful sexual intercourse patient undergo hormone therapy .</brief_summary>
	<brief_title>Fluocinonide Cream Treating Symptoms Vaginal Dryness Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate decrease symptom vaginal dryness dyspareunia use fluocinonide 0.05 % cream breast cancer subject subject increase risk breast cancer endocrine therapy . Estimates decrease obtain utilizing patient survey instrument . SECONDARY OBJECTIVES : I . To estimate decrease symptom vaginal itching total vaginal index score use fluocinonide 0.05 % cream breast cancer subject subject increase risk breast cancer endocrine therapy . Estimates decrease obtain utilizing patient survey instrument . II . To explore toxicity report subject use fluocinonide 0.05 % cream via vaginal application . III . To explore correlation subject report compliance , well compliance via measurement amount fluocinonide 0.05 % cream use , response rate use fluocinonide 0.05 % cream . IV . To explore correlation patient characteristic response rate use fluocinonide 0.05 % cream . OUTLINE : Patients apply topical fluocinonide cream twice daily ( BID ) week 1-2 daily ( QD ) week 3-4 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluocinonide</mesh_term>
	<criteria>Adult woman ( premenopausal postmenopausal woman eligible ) history breast cancer increase risk breast cancer current treatment tamoxifen aromatase inhibitor presence vaginal dryness dyspareunia sufficient severity make subject patient desire therapeutic intervention Vaginal dryness dyspareunia must present least two month prior study entry Subjects must current treatment tamoxifen aromatase inhibitor least two month prior study enrollment ( defined date consent ) planning discontinue treatment change dose type endocrine treatment duration study Subjects must agree use overthecounter prescription vaginal preparation ( lubricant , cream , gel , ointment , solution ) four week treatment topical fluocinonide cream Subjects must agree use medication , product , preparation know contain estrogen four week treatment topical fluocinonide cream Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Subjects must ability read , comprehend , complete patient questionnaire independently assistance Subjects must sign informed consent Subjects must agree read patient instruction regard use barrier contraceptive device treatment fluocinonide cream inform consent Use vaginal preparation within one week prior study enrollment ( exception : subject currently use vaginal preparation enroll discontinue treatment 7 day ) Use estrogen containing medication , product , preparation Use systemic oral parenteral steroid contain medication permit ; use `` High Daily Dose '' inhaled/intranasal corticosteroid permit ; use inhaled/intranasal corticosteroid preparation dose level less `` High Daily Dose '' permit Current past treatment fluocinonide cream vaginal dryness , itching , dyspareunia Subject report symptoms vaginal infection significant vaginal discharge odor Known current vaginal infection Known vaginal pathology vaginal atrophy could explain vaginal symptom Known intolerance topical steroid preparation Pregnant lactate woman ( obtain via subject report ) Known diagnose diabetes mellitus , adrenal insufficiency ( Addison 's disease ) , Cushing 's syndrome No prior chemotherapeutic treatment malignancy breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>